Using Atrial Fibrillation Burden Trends and Machine Learning to Predict Near-Term Risk of Cardiovascular Hospitalization
- PMID: 39445440
- PMCID: PMC11575902
- DOI: 10.1161/CIRCEP.124.012991
Using Atrial Fibrillation Burden Trends and Machine Learning to Predict Near-Term Risk of Cardiovascular Hospitalization
Abstract
Background: Atrial fibrillation is associated with an increased risk of cardiovascular hospitalization (CVH), which may be triggered by changes in daily burden. Machine learning of dynamic trends in atrial fibrillation burden, as measured by insertable cardiac monitors (ICMs), may be useful in predicting near-term CVH.
Methods: Using Optum's deidentified Clinformatics Data Mart Database (2007-2019), linked with the Medtronic CareLink ICM database, we identified patients with >1 days of ICM-detected atrial fibrillation. ICM-detected diagnostic parameters were transformed into simple moving averages over different periods for daily follow-up. A diagnostic trend was defined as the comparison of 2 simple moving averages of different periods for each diagnostic parameter. CVH was defined as any hospital, emergency department, or ambulatory surgical center encounter with a cardiovascular diagnosis-related group or diagnosis code. Machine learning was used to determine which diagnostic trends could best predict patient risk 5 days before CVH.
Results: A total of 2616 patients with ICMs met the inclusion criteria (71±11 years; 55% male). Among them, 1998 (76%) had a planned or unplanned CVH over 605 363 days. Machine learning revealed distinct groups: (A) sinus rhythm (reference), (B) below-average burden, (C) above-average burden, and (D) above-average burden with decreasing patient activity. The relative risk was increased in all groups versus the reference (B, 4.49 [95% CI, 3.74-5.40]; C, 8.41 [95% CI, 7.00-10.11]; D, 11.15 [95% CI, 9.10-13.65]), including a 21% increase in CVH detection over prespecified burden thresholds of duration (≥1 hour) and quantity (≥5%). The area under the receiver operating characteristic curve increased from 0.55 when using hourly burden amounts to 0.66 when using burden trends and decreasing patient activity (P<0.001), a 20% increase in predictive power.
Conclusions: Trends in atrial fibrillation were strongly associated with near-term CVH, especially above-average burden coupled with low patient activity. This approach could provide actionable information to guide treatment and reduce CVH.
Keywords: atrial fibrillation; data warehousing; hospitals; humans; risk.
Conflict of interest statement
Dr Peacock serves as a consultant to Medtronic and Biotronik. E.J. Stanelle, Dr Johnson, and R. Kanwar are employed by Medtronic. D. Soderlund was formerly employed by Medtronic. Dr Hylek serves as a consultant for Bayer, Bristol Myers Squibb, Ionis, Janssen, and Pfizer, receives research grants from Abbott, Anthos Therapeutics, and Medtronic, and receives honoraria from Boehringer Ingelheim. Dr Lakkireddy serves as a consultant to Medtronic, Boston Scientific, Abbott, Atricure, AltaThera, Acutus, and AliveCor. Dr Mittal serves as a consultant to Abbott, Boston Scientific, and Medtronic. Dr Passman is supported by UG3HL165065 from NHLBI 18SFRN34250013 from the American Heart Association (AHA), receives a grant for clinical research from Abbott, serves as a consultant to Medtronic, Janssen Pharmaceuticals, and Abbott, and receives royalties from UpToDate. Dr Russo serves as a consultant for Abbott, Atricure, Bayer, Biosense Webster, Boston Scientific, Medtronic, and PaceMate receives grants for clinical research from Boston Scientific, Kestra, Medilynx, and Medtronic and receives honoraria from Biotronik, Bristol Myers Squibb, Pfizer, Medtronic, and Sanofi. Dr Piccini is supported by R01AG074185 from the National Institute on Aging receives grants for clinical research from Abbott, AHA, the Association for the Advancement of Medical Instrumentation, Bayer, Boston Scientific, iRhythm, and Philips serves as a consultant to Abbott, AbbVie, Ablacon, AltaThera, ARCA Biopharma, Biotronik, Boston Scientific, Bristol Myers Squibb, LivaNova, Medtronic, Milestone, Electrophysiology Frontiers, Pfizer, Sanofi, Philips, and UptoDate. The other author report no conflicts.
Figures




References
-
- Chen LY, Chung MK, Allen LA, Ezekowitz M, Furie KL, McCabe P, Noseworthy PA, Perez MV, Turakhia MP; American Heart Association Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; Council on Quality of Care and Outcomes Research; and Stroke Council. Atrial fibrillation burden: moving beyond atrial fibrillation as a binary entity: a scientific statement from the American Heart Association. Circulation. 2018;137:e623–e644. doi: 10.1161/CIR.0000000000000568 - PMC - PubMed
-
- Steinberg BA, Piccini JP. When low-risk atrial fibrillation is not so low risk: beast of burden. JAMA Cardiol. 2018;3:558–560. doi: 10.1001/jamacardio.2018.1205 - PubMed
-
- Chew DS, Li Z, Steinberg BA, O’Brien EC, Pritchard J, Bunch TJ, Mark DB, Patel MR, Nabutovsky Y, Greiner MA, et al. . Arrhythmic burden and the risk of cardiovascular outcomes in patients with paroxysmal atrial fibrillation and cardiac implanted electronic devices. Circ Arrhythm Electrophysiol. 2022;15:e010304. doi: 10.1161/CIRCEP.121.010304 - PubMed
-
- Steinberg BA, Hellkamp AS, Lokhnygina Y, Patel MR, Breithardt G, Hankey GJ, Becker RC, Singer DE, Halperin JL, Hacke W, et al. ; on behalf of the ROCKET-AF Steering Committee and Investigators. Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF trial. Eur Heart J. 2015;36:288–296. doi: 10.1093/eurheartj/ehu359 - PMC - PubMed
-
- Piccini JP, Passman R, Turakhia M, Connolly AT, Nabutovsky Y, Varma N. Atrial fibrillation burden, progression, and the risk of death: a case-crossover analysis in patients with cardiac implantable electronic devices. Europace. 2019;21:404–413. doi: 10.1093/europace/euy222 - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous